1 Introduction 7

• 1.1 Industry Definition and Research Scope 7
  • 1.1.1 Industry Definition 7
  • 1.1.2 Research Scope 8
• 1.2 Research Methodology 11
  • 1.2.1 Overview of Market Research Methodology 11
  • 1.2.2 Market Assumption 12
  • 1.2.3 Secondary Data 12
  • 1.2.4 Primary Data 12
  • 1.2.5 Data Filtration and Model Design 14
  • 1.2.6 Market Size/Share Estimation 15
  • 1.2.7 Research Limitations 16
• 1.3 Executive Summary 17

2 Market Overview and Dynamics 20

• 2.1 Market Size and Forecast 20
  • 2.1.1 Impact of COVID-19 on the Market 25
• 2.2 Major Growth Drivers 27
• 2.3 Market Restraints and Challenges 32
• 2.4 Emerging Opportunities and Market Trends 37
• 2.5 Porter’s Fiver Forces Analysis 41

3 Segmentation of Europe Market by System Component 45

• 3.1 Market Overview by System Component 45
• 3.2 Data Collection Tools 47
  • 3.2.1 Digital Platforms 49
  • 3.2.2 Mobile Apps 50
  • 3.2.3 Desktop-based Software 51
  • 3.2.4 Wearables 52
  • 3.2.5 Biosensors 53
• 3.3 Data Integration Systems 54

4 Segmentation of Europe Market by Therapeutic Area 55

• 4.1 Market Overview by Therapeutic Area 55
• 4.2 Cardiovascular Diseases 57
• 4.3 Neurodegenerative Disorders 58
  • 4.3.1 Parkinson’s Disease 60
  • 4.3.2 Multiple Sclerosis 61
  • 4.3.3 Alzheimer’s Disease 62
• 4.4 Sleep and Movement Diseases 63
• 4.5 Psychiatric Disorders 64
• 4.6 Chronic Pain 65
• 4.7 Gastrointestinal Diseases 66
• 4.8 Diabetes 67
• 4.9 Respiratory Conditions 68
• 4.10 Other Diseases 69

5 Segmentation of Europe Market by Application 70

• 5.1 Market Overview by Application 70
• 5.2 Wellness 72
• 5.3 Disease Diagnosis 73
• 5.4 Personalised Medication 74
• 5.5 Drug Discovery and Development 75

6 Segmentation of Europe Market by Development Status 77

• 6.1 Market Overview by Development Status 77
• 6.2 Novel Digital Biomarkers 80
• 6.3 Original Digital Biomarkers 81
• 6.4 Approved Digital Biomarkers 82

7 Segmentation of Europe Market by End User 83

• 7.1 Market Overview by End User 83
• 7.2 Biopharmaceutical Companies & Labs 85
• 7.3 Healthcare Providers 86
• 7.4 Insurance Payers 87

8 European Market 2019-2030 by Country 88

• 8.1 Overview of European Market 88
• 8.2 Germany 91
• 8.3 UK 93
• 8.4 France 95
• 8.5 Netherlands 97
• 8.6 Italy 99
• 8.7 Russia 101
• 8.8 Rest of European Market 103

9 Competitive Landscape 105

• 9.1 Overview of Key Vendors 105
• 9.2 New Product Launch, Partnership, Investment, and M&A 109
• 9.3 Company Profiles 110

Actigraph LLC 110

Akili Interactive Labs 112

AliveCor Inc 113

Altoida Inc 114

Amgen Inc 115

Bayer AG 116

Biogen Inc 117

Cambridge Cognition Plc 118

Eli Lilly and Company 119

Evidation Health, Inc. 120

F. Hoffmann-La Roche Ltd 121

Fitbit Inc 122

GlaxoSmithKline Plc 123

Happify Health 124

Human API 125

IXICO Plc 126

Koninklijke Philips N.V. 127

Medical Care Corporation 128

Medopad Ltd 129

Mindstrong Health 130

Neurotrack Technology, Inc 131

Novartis International AG 132

Pfizer Inc. 133

Quanterix Corporation 134

Sanofi S.A. 135

The Takeda Pharmaceuticals Company Limited 136

Verily Life Sciences 137

Winterlight Labs Inc. 138

10 Investing in Europe Market: Risk Assessment and Management 139

• 10.1 Risk Evaluation of Europe Market 139
• 10.2 Critical Success Factors (CSFs) 142

Related Reports and Products 145

Europe digital biomarkers market accounted for $118.0 million in 2019 and will grow by 40.3% annually over 2020-2030 owing to the rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare amid COVID-19 epidemic.
Highlighted with 42 tables and 67 figures, this 145-page report “Europe Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe digital biomarkers market in every aspect of the classification from perspectives of System Component, Therapeutic Area, Application, Development Status, End User, and Country.

Based on System Component, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Data Collection Tools
• Digital Platforms
• Mobile Apps
• Desktop-based Software
• Wearables
• Biosensors
Data Integration Systems

Based on Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Cardiovascular Diseases
Neurodegenerative Disorders
• Parkinson’s Disease
• Multiple Sclerosis
• Alzheimer’s Disease
Sleep and Movement Diseases
Psychiatric Disorders
Chronic Pain
Gastrointestinal Diseases
Diabetes
Respiratory Conditions
Other Diseases

Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Wellness
• Disease Diagnosis
• Personalised Medication
• Drug Discovery and Development

Based on Development Status, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Novel Digital Biomarkers
• Original Digital Biomarkers
• Approved Digital Biomarkers

Based on End User, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Biopharmaceutical Companies & Labs
• Healthcare Providers
• Insurance Payers

Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Netherlands
• Italy
• Russia
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, Spain, Poland, Czech Republic, Slovakia, Hungary, and Romania)
For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by System Component, Therapeutic Area, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe digital biomarkers market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Actigraph LLC
Akili Interactive Labs
AliveCor Inc
Altoida Inc
Amgen Inc
Bayer AG
Biogen Inc
Cambridge Cognition Plc
Eli Lilly and Company
Evidation Health, Inc.
F. Hoffmann-La Roche Ltd
Fitbit Inc
GlaxoSmithKline Plc
Happify Health
Human API
IXICO Plc
Koninklijke Philips N.V.
Medical Care Corporation
Medopad Ltd
Mindstrong Health
Neurotrack Technology, Inc
Novartis International AG
Pfizer Inc.
Quanterix Corporation
Sanofi S.A.
The Takeda Pharmaceuticals Company Limited
Verily Life Sciences
Winterlight Labs Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)